These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32848857)

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction.
    Peng X; Li L; Zhang M; Zhao Q; Wu K; Bai R; Ruan Y; Liu N
    Front Physiol; 2020; 11():912. PubMed ID: 32848857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors.
    Donniacuo M; De Angelis A; Telesca M; Bellocchio G; Riemma MA; Paolisso P; Scisciola L; Cianflone E; Torella D; Castaldo G; Capuano A; Urbanek K; Berrino L; Rossi F; Cappetta D
    Pharmacol Res; 2023 Feb; 188():106591. PubMed ID: 36502999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
    Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
    Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
    Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
    Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
    Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
    J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
    Wang M; Zhang Y; Wang Z; Liu D; Mao S; Liang B
    J Thorac Dis; 2022 May; 14(5):1620-1637. PubMed ID: 35693625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis.
    Zhao Z; Jiang C; He L; Zheng S; Wang Y; Gao M; Lai Y; Zhang J; Li M; Dai W; Zuo S; Guo X; Li S; Jiang C; Liu N; Tang R; Long D; Du X; Sang C; Dong J; Ma C
    J Am Heart Assoc; 2023 Dec; 12(24):e031269. PubMed ID: 38084708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
    Kishima H; Mine T; Fukuhara E; Kitagaki R; Asakura M; Ishihara M
    JACC Clin Electrophysiol; 2022 Nov; 8(11):1393-1404. PubMed ID: 36424008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients.
    Liu HT; Wo HT; Chang PC; Lee HL; Wen MS; Chou CC
    Heliyon; 2023 Jun; 9(6):e16835. PubMed ID: 37332966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
    Yurista SR; Silljé HHW; Rienstra M; de Boer RA; Westenbrink BD
    Cardiovasc Diabetol; 2020 Jan; 19(1):5. PubMed ID: 31910841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    J Clin Endocrinol Metab; 2024 Mar; ():. PubMed ID: 38466894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.